The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform.

PLoS One · 2013 · PMC3602083 · PMID 23527252

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

Adjusted, multivariable modelling further revealed that older age at treatment start (HR 0.79 per 10 years, p<0.000) was an independent predictor of treatment persistence, and an EDSS of 3.0–5.5 as compared to an EDSS of zero approached significance as an independent predictor of treatment discontinuation ( Figure 1b ).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.